AstraZeneca Stock - FDA expands Truqap label as chart picture improves
18.06.2026 - 13:30:56 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 13:30 CET. Details in the imprint.
AstraZeneca (US6549022043) is back in the spotlight after the US Food and Drug Administration expanded the label for its cancer drug Truqap to include a metastatic prostate cancer indication, according to a Zacks news summary dated 06/16/2026. The fresh approval comes as the stock’s technical picture has turned more constructive in recent sessions.
All news and analysis on AstraZeneca stock
Background reports, real-time prices and further company news on AstraZeneca stock can be found in the dedicated topic area and on the company’s investor-relations pages.
New FDA nod for Truqap
According to a Zacks report dated 06/16/2026, the FDA has approved AstraZeneca’s targeted therapy Truqap (capivasertib) for use alongside abiraterone and prednisone in adults with PTEN-deficient metastatic prostate cancer. This adds another oncology indication to the drug’s profile.
The same report notes that AstraZeneca had already secured an earlier approval for Truqap in certain breast cancer settings, highlighting the company’s push to broaden its late-stage oncology portfolio. Management has presented Truqap as one of several next-generation targeted therapies intended to support growth beyond 2030.
Chart picture on Thursday
A separate technical write-up from Traders Union states that AstraZeneca shares recently traded around GBX13,484 in London, edging up 0.09% on the day while holding above their 20-day and 50-day moving averages but still below the 200-day line. This suggests modest short-term momentum within a longer consolidation.
The analysis cites a 20-day moving average near GBX13,309 and a 50-day moving average around GBX13,427, with the longer-term 200-day line near GBX13,602. From a pure chart perspective, AstraZeneca currently trades between medium-term support and a still-untaken longer-term resistance band.
The product behind the stock
AstraZeneca generates most of its revenue from prescription medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare disease. Truqap, a targeted AKT inhibitor, now contributes to the oncology franchise alongside blockbuster brands such as Tagrisso and Imfinzi according to company materials. Company therapy-area overview
Where the stock trades today
Shares of AstraZeneca (US6549022043) most recently changed hands on the London Stock Exchange at about GBX13,484.00 as of 06/18/2026, 12:30 BST.
Key facts on AstraZeneca stock
- Company: AstraZeneca PLC
- ISIN: US6549022043
- WKN: 886455
- Ticker: AZN
- Venue: London Stock Exchange
- Price (as of 06/18/2026, 12:30 BST): 13,484.00 GBX
- Market cap: 210,000,000,000 GBP (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: FTSE 100
- Next earnings date: 07/25/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
